Fig. 7
Time of addition of G2-S16 or G2-S24P dendrimer and their combinations with ganciclovir. Plaque reduction assays were performed in MRC-5 cells for 6 days. MRC-5 cells were seeded, infected with 60 PFU and treated at different time points (0, 24, 48, 72 and 96 h post-infection) with either a ganciclovir, G2-S16 dendrimer and G2-S16 dendrimer + ganciclovir combination b ganciclovir, G2-S24P dendrimer, and G2-S24P + ganciclovir. Plaques were counted after 6 days with a methylene blue dye. Percentage of HCMVAD−169 infection is represented as the number of plaques in treatments in regard of the control of HCMVAD−169 infection. CI: Control of infection, NT: non-treated control. The mean values (mean ± SD) of at least four independent experiments are shown (*p < 0.05; **p < 0.005; ***p < 0.001)